Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cohesion

This article was originally published in The Gray Sheet

Executive Summary

Newly appointed VP-Operations James Barnes is charged with improving the surgical sealant manufacturer's gross margins. Barnes previously held the same position at minimally invasive surgical access product manufacturer InnerDyne, which was purchased by Tyco subsidiary U.S. Surgical in October 2000. Barnes, 49, follows new President and CEO William Mavity, appointed Oct. 1. Mavity, 51, formerly served as president and CEO of InnerDyne (1"The Gray Sheet" Sept. 24, 2001, p. 32). Seperately, a planned restructuring will include a $1.5 mil. cut from the biosurgery firm's annual R&D budget and a 20% workforce reduction. The move will shift resources to operations, sales and marketing of existing technology platforms including the firm's CoStasis surgical hemostat, approved in June 2000, and CoSeal surgical sealant, currently under PMA review. A related charge of $500,000 to $600,000 will be recorded in the quarter ending Dec. 31...

You may also be interested in...



Cohesion CoSeal Launch Set For Late January At Thoracic Surgery Meeting

Cohesion Technologies believes that the broad vascular reconstruction indication for its CoSeal surgical sealant makes it less imperative for the firm to pursue site-specific indications immediately

Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

UK Medtechs Must Face Up To Brexit Certainty After Election Result

The December 12 UK general election returned a Conservative majority, the scale or which few would have predicted. It means that the  new government can press on with its plans for Brexit, the uncertainty now surrounding only when, not if.

UsernamePublicRestriction

Register

MT015735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel